Literature DB >> 21403574

Changing trends in cleft lip and palate management taught in training programs in Korea.

Jin Sup Eom1, Taik Jong Lee.   

Abstract

To assess changes in trends of cleft management and achieve an overview of the current status, a replication of 2000 national survey was conducted. Questionnaires containing 46 categories were distributed to 72 senior residents of all Korean institutes with plastic surgery training programs. Forty-two of the questionnaires were returned in completed form. The results were (1) new surgeries numbering less than 10 per year were reported by 50% for the cleft lip and by 45% for the cleft palate; (2) 61% were using presurgical orthopedics before the repair of the cleft, and most common method was presurgical nasal-alveolar molding (43%); (3) the rotation advancement technique (94%) was the most popular method for the unilateral cleft lip repair and the Millard method (54%) for the bilateral cleft lip repair; (5) the double-opposing Z-plasty was the most common method for the repair of the complete (56%) and the incomplete cleft palate (80%); (6) 85% of the respondents reported performed the alveolar cleft repair during the period of mixed dentition, and the gingival mucoperiosteal flap and bone graft method was the most favored methods (92%); (7) the multidisciplinary team approach was practiced by 36%. Although the current result cannot be regarded as a significant advance in cleft management, the overall cleft services in Korea were getting standardized and shown to be turning to more efficient structure.

Entities:  

Mesh:

Year:  2011        PMID: 21403574     DOI: 10.1097/SCS.0b013e31820745e1

Source DB:  PubMed          Journal:  J Craniofac Surg        ISSN: 1049-2275            Impact factor:   1.046


  1 in total

1.  Preliminary study of Korean orthodontic residents' current concepts and knowledge of cleft lip and palate management.

Authors:  Il-Sik Cho; Hyo-Keun Shin; Seung-Hak Baek
Journal:  Korean J Orthod       Date:  2012-06-28       Impact factor: 1.372

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.